Corton Capital’s Keros Therapeutics KROS Stock Holding History

Corton Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,212	Closed	-$186K	–	377
2025 Q1	$186K	Buy	+18,212	New	+$211K	0.61%	76

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Corton Capital's KROS Position: Q2 2025 in Review

Corton Capital sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 18,212 shares — an estimated $186K sold.

Corton Capital first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $186K in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

Corton Capital reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
Corton Capital sold 18,212 Keros Therapeutics shares in Q2 2025, an estimated $186K.
Corton Capital first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
Corton Capital's Keros Therapeutics position peaked at $186K in Q1 2025.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.